Diagnosis, treatment, response monitoring, and outcome of pediatric acute myeloid
leukemia (AML) have made enormous progress during the past decades. Because AML is a …

JCM | Free Full-Text | Pediatric Acute Myeloid Leukemia—Past, Present, and Future Next
Article in Journal Sexual Habits and Sexual Dysfunctions in a Sample of Patients with Psychotic …

We conducted a clinical trial to assess the feasibility and efficacy of CD33-directed chimeric
antigen receptor-modified T cells (CART-33) for the treatment of refractory acute myeloid …

Transient abnormal myelopoiesis (TAM) is a myeloid proliferation resembling acute
megakaryoblastic leukemia (AMKL), mostly affecting perinatal infants with Down syndrome …

Pediatric acute myeloid leukemia (AML) represents 15%–20% of all pediatric acute
leukemias. Survival rates have increased over the past few decades to~ 70%, due to …

Further incorporation of genomic and molecular data in pediatric AML will allow for
additional refinements in risk stratification to enable the tailoring of treatment intensity. These …

Pediatric acute myeloid leukemia is a rare and heterogeneous disease in relation to
morphology, immunophenotyping, germline and somatic cytogenetic and genetic …

We and others previously reported potent antileukemia efficacy of CD123-redirected
chimeric antigen receptor (CAR) T cells in preclinical human acute myeloid leukemia (AML) …

PURPOSE A previous study by the International Berlin-Frankfurt-Münster Study Group (I-
BFM-SG) on childhood KMT2A-rearranged (KMT2A-r) AML demonstrated the prognostic …

Antibody-based immunotherapy represents a promising strategy to target and eliminate
chemoresistant leukemic cells. Here, we evaluated the CD33/CD3-bispecific T cell engaging …